Side-by-side comparison of AI visibility scores, market position, and capabilities
Dutch health technology company with €17B revenue; MRI/CT imaging and patient monitoring managing massive sleep apnea device recall competing with Siemens Healthineers and GE HealthCare.
Philips is a Dutch multinational technology and health technology company that has transformed from a broad consumer electronics conglomerate into a focused health technology leader — producing diagnostic imaging systems (MRI, CT, ultrasound), patient monitoring, hospital informatics, personal health products (electric toothbrushes, shavers, sleep apnea devices), and health informatics solutions. Listed on the Amsterdam Stock Exchange (AEX: PHIA) and headquartered in Amsterdam, Philips generates approximately €17 billion ($18 billion) in annual revenue after divesting its lighting division (now Signify) and domestic appliances business.\n\nPhilips' health technology portfolio spans two segments: Diagnosis & Treatment (imaging systems, image-guided therapy, and ultrasound for hospitals) and Connected Care (patient monitoring, respiratory care, sleep therapy). The Diagnosis & Treatment segment provides MRI systems, CT scanners, and X-ray equipment to hospitals globally. The Connected Care segment includes Philips' DreamStation and other sleep apnea (CPAP/BiPAP) devices, home respiratory care, and hospital patient monitoring platforms.\n\nIn 2025, Philips is managing the severe consequences of a 2021 recall of approximately 5.5 million sleep apnea devices (Philips Respironics DreamStation and related models) due to concerns that degraded polyester foam could release harmful particles and gases — one of the largest medical device recalls in history. The recall has resulted in multi-billion dollar settlements, regulatory scrutiny, and significant reputation damage in the sleep therapy market, allowing competitors ResMed and Fisher & Paykel to gain share. Philips' 2025 strategy focuses on resolving recall liabilities, rebuilding the sleep therapy business, and investing in AI-powered diagnostic imaging to compete with Siemens Healthineers and GE HealthCare.
Cambridge/Colorado trapped-ion quantum computing (Honeywell majority; $625M+/$5B valuation Jun 2024); Helios Nov 2025 at 98 physical/48 logical qubits with 99.9975% fidelity serving Amgen/BMW/JPMorgan competing with IBM Quantum.
Quantinuum is a Cambridge, UK and Broomfield, Colorado-based integrated quantum computing company — majority owned by Honeywell (NASDAQ: HON) with $625+ million in total funding including a $300 million round led by JPMorgan Chase at a $5 billion valuation in June 2024 — operating the world's most accurate commercial quantum computers using trapped-ion technology combined with quantum software from Cambridge Quantum. In November 2025, Quantinuum launched Helios, its third-generation quantum computer featuring 98 physical qubits and 48 logical error-corrected qubits with 99.9975% single-qubit gate fidelity and 99.921% two-qubit gate fidelity — the highest-accuracy general-purpose commercial quantum computer commercially available. Serving enterprise customers including Amgen (drug discovery), BMW Group (materials simulation), JPMorgan Chase (financial optimization), and SoftBank Corp. (AI acceleration), Quantinuum was formed in November 2021 through the merger of Honeywell Quantum Solutions and Cambridge Quantum Computing. CEO Ilyas Khan.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.